HK1199409A1 - Antibodies binding to phosphorylcholine (pc) and/or pc conjugates (pc)/ pc - Google Patents

Antibodies binding to phosphorylcholine (pc) and/or pc conjugates (pc)/ pc

Info

Publication number
HK1199409A1
HK1199409A1 HK14113055.9A HK14113055A HK1199409A1 HK 1199409 A1 HK1199409 A1 HK 1199409A1 HK 14113055 A HK14113055 A HK 14113055A HK 1199409 A1 HK1199409 A1 HK 1199409A1
Authority
HK
Hong Kong
Prior art keywords
phosphorylcholine
conjugates
antibodies binding
antibodies
binding
Prior art date
Application number
HK14113055.9A
Other languages
English (en)
Chinese (zh)
Inventor
．彼得松
．坎貝爾
丹．塞克斯頓
安德魯．
．尼克松
Original Assignee
Athera Biotechnologies Ab
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab, Dyax Corp filed Critical Athera Biotechnologies Ab
Publication of HK1199409A1 publication Critical patent/HK1199409A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14113055.9A 2011-08-09 2014-12-30 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates (pc)/ pc HK1199409A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161521607P 2011-08-09 2011-08-09
PCT/US2012/049990 WO2013022968A1 (en) 2011-08-09 2012-08-08 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Publications (1)

Publication Number Publication Date
HK1199409A1 true HK1199409A1 (en) 2015-07-03

Family

ID=47668922

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113055.9A HK1199409A1 (en) 2011-08-09 2014-12-30 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates (pc)/ pc

Country Status (8)

Country Link
US (3) US9796786B2 (de)
EP (1) EP2741770A4 (de)
JP (1) JP6277126B2 (de)
CN (1) CN103906532B (de)
AU (1) AU2012294431B2 (de)
CA (1) CA2843960C (de)
HK (1) HK1199409A1 (de)
WO (1) WO2013022968A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741770A4 (de) * 2011-08-09 2014-12-31 Athera Biotechnologies Ab Antikörperbindung an phosphorylcholin (pc) und/oder pc-konjugate
AR087485A1 (es) 2011-08-09 2014-03-26 Athera Biotechnologies Ab Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
WO2014131034A2 (en) * 2013-02-25 2014-08-28 The Regents Of The University Of California Antibodies to oxidized phospholipids
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
MX2018009011A (es) 2016-02-02 2018-11-19 Hutchinson Fred Cancer Res Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3751182T2 (de) 1986-08-06 1995-10-26 Scripps Clinic Res Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
AU5522390A (en) 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
JP3183665B2 (ja) 1990-12-10 2001-07-09 エントルメド インコーポレーテッド コレステロール過剰血症およびアテローム性動脈硬化を防止するためのコレステロールに体するワクチン
WO1993018161A1 (en) 1992-03-03 1993-09-16 The Rockefeller University Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
ES2205853T3 (es) 1998-07-03 2004-05-01 Athera Biotechnologies Ab Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz.
ATE506615T1 (de) 1999-10-26 2011-05-15 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
WO2001088547A2 (en) 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay
KR101155294B1 (ko) * 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2004091520A2 (en) 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
CN1968965B (zh) * 2004-04-15 2015-12-16 阿瑟拉生物技术公司 磷酸胆碱偶联物和相应抗体
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP1793004B1 (de) 2004-09-08 2010-03-31 Eisai R&D Management Co., Ltd. Verfahren zur bildung eines signalsondenpolymers
CA2604683C (en) * 2005-04-12 2019-04-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
AU2009267417A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for Alzheimer's disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
AR087485A1 (es) 2011-08-09 2014-03-26 Athera Biotechnologies Ab Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
EP2741770A4 (de) * 2011-08-09 2014-12-31 Athera Biotechnologies Ab Antikörperbindung an phosphorylcholin (pc) und/oder pc-konjugate

Also Published As

Publication number Publication date
CA2843960C (en) 2020-09-15
CN103906532A (zh) 2014-07-02
CA2843960A1 (en) 2013-02-14
US20180086847A1 (en) 2018-03-29
EP2741770A4 (de) 2014-12-31
AU2012294431B2 (en) 2017-03-30
WO2013022968A1 (en) 2013-02-14
JP2014529398A (ja) 2014-11-13
US20140193413A1 (en) 2014-07-10
AU2012294431A1 (en) 2014-02-20
JP6277126B2 (ja) 2018-02-07
US9796786B2 (en) 2017-10-24
US20210230310A1 (en) 2021-07-29
EP2741770A1 (de) 2014-06-18
CN103906532B (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
IL271804A (en) Mice producing binding proteins containing VL domains
HUS1900048I1 (hu) Anti-IL-23 antitestek
ZA201304905B (en) TNF-a BINDING PROTEINS
SG10201401681PA (en) Novel antigen binding proteins
IL222980A0 (en) Il-1 binding proteins
ZA201205624B (en) Cd127 binding proteins
IL222852A0 (en) Anti-fgfr2 antibodies
ZA201208906B (en) Humanised antigen binding proteins to myostatin6
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
PT2609119T (pt) Proteínas de ligação ao antigénio de polissacáridos quitinosos
IL225571A0 (en) Antibodies
IL226157A0 (en) Antigen binding proteins
HK1199409A1 (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates (pc)/ pc
GB201016809D0 (en) Improvements in relation to antibody binding
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220805